Targets › JAK3
16 programs from 14 companies in 184 trials: 80 Phase 2, 46 Phase 3, 38 Phase 1, 20 Phase 4; Immunology, Oncology, Other; next expected readout Nov 2026.
Non-receptor tyrosine kinase involved in various processes such as cell growth, development, or differentiation. Mediates essential signaling events in both innate and adaptive immunity and plays a crucial role in hematopoiesis during T-cells development. (UniProt, P52333)
Open in Phaseline: the race on JAK3, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Takeda | Tofacitinib Janus Kinase (JAK) inhibitor | JAK3, JAK1, JAK2, TYK2 | Phase 4 | Ulcerative Colitis; Rheumatoid Arthritis; Axial Spondyloarthritis; Oral Lichen Planus … | Jul 2027 |
| Eisai | Filgotinib Maleate Tyrosine-protein kinase JAK1 inhibitor; Tyrosine-protein kinase JAK2 inhibitor; Tyrosine-protein kinase TYK2 inhibitor | JAK1, JAK2, TYK2, JAK3 | Phase 4 | Ulcerative Colitis | Nov 2027 |
| Incyte | Ruxolitinib Tyrosine-protein kinase JAK1 inhibitor; Tyrosine-protein kinase JAK2 inhibitor; Tyrosine-protein kinase JAK3 inhibitor | JAK1, JAK2, JAK3, TYK2 | Phase 3 | NonSegmental Vitiligo; Hidradenitis Suppurativa; Atopic Dermatitis; Graft-versus-host Disease (GVHD) … | Nov 2026 |
| AbbVie | Upadacitinib Tyrosine-protein kinase TYK2 inhibitor; Tyrosine-protein kinase JAK3 inhibitor; Tyrosine-protein kinase JAK2 inhibitor | TYK2, JAK3, JAK2, JAK1 | Phase 3 | Atopic Dermatitis; Systemic Lupus Erythematosus; Ulcerative Colitis (UC); Crohn's Disease … | Nov 2026 |
| Pfizer | Ritlecitinib Tyrosine-protein kinase JAK3 inhibitor; TEC family kinase inhibitor | JAK3, ITK, BMX, TEC, TXK | Phase 3 | Severe Alopecia Areata; Vitiligo; Stable Nonsegmental Vitiligo; Alopecia Areata … | Dec 2026 |
| LEO Pharma | Delgocitinib Janus Kinase (JAK) inhibitor | JAK3, JAK1, JAK2, TYK2 | Phase 3 | Lichen Sclerosus; Palmoplantar Pustulosis; Central Centrifugal Cicatricial Alopecia; Vitiligo | Dec 2026 |
| Pfizer | tofacitinib Janus Kinase (JAK) inhibitor | JAK3, JAK1, JAK2, TYK2 | Phase 3 | Ulcerative Colitis | Mar 2027 |
| Sun Pharmaceutical Industries | Deuruxolitinib Phosphate (CTP-543) Tyrosine-protein kinase JAK1 inhibitor; Tyrosine-protein kinase JAK2 inhibitor; Tyrosine-protein kinase JAK3 inhibitor | JAK1, JAK2, JAK3, TYK2 | Phase 3 | Alopecia Areata | May 2027 |
| Alfasigma | Filgotinib Tyrosine-protein kinase JAK1 inhibitor; Tyrosine-protein kinase JAK2 inhibitor; Tyrosine-protein kinase TYK2 inhibitor | JAK1, JAK2, TYK2, JAK3 | Phase 3 | Polyarticular Course Juvenile Idiopathic Arthritis; Juvenile Idiopathic Arthritis (JIA); Ulcerative Colitis; Axial Spondyloarthritis … | Jun 2027 |
| Suzhou Zelgen Biopharmaceuticals | Jaktinib Hydrochloride Tablet JAK inhibitor | JAK1, JAK2, JAK3 | Phase 3 | Atopic Dermatitis | – |
| M.D. Anderson Cancer Center | Ruxolitinib Phosphate Tyrosine-protein kinase JAK1 inhibitor; Tyrosine-protein kinase JAK2 inhibitor; Tyrosine-protein kinase JAK3 inhibitor | JAK1, JAK2, JAK3, TYK2 | Phase 2 | Splenomegaly; AML; Chronic Lymphocytic Leukemia; T-cell Prolymphocytic Leukemia … | Jan 2027 |
| Fudan University | SHR-0302 JAK inhibitor | JAK1, JAK2, JAK3 | Phase 2 | Relapsed/Refractory Peripheral T Cell Lymphoma | Feb 2027 |
| City of Hope Medical Center | Ruxolitinib Phosphate Tyrosine-protein kinase JAK1 inhibitor; Tyrosine-protein kinase JAK2 inhibitor; Tyrosine-protein kinase JAK3 inhibitor | JAK1, JAK2, JAK3, TYK2 | Phase 2 | Acute Lymphoblastic Leukemia; Follicular Helper T-Cell Lymphoma; Hematopoietic and Lymphatic System Neoplasm | Mar 2027 |
| Shixiu Wu | JAK Inhibitors Janus kinase inhibitors | JAK1, JAK2, JAK3, TYK2 | Phase 2 | Immune Checkpoint Inhibitors (ICI)-Related Dermatitis | – |
| AbbVie | Tofacitinib Janus Kinase (JAK) inhibitor | JAK3, JAK1, JAK2, TYK2 | Phase 1 | Healthy Volunteers | Dec 2026 |
| First Affiliated Hospital of Zhejiang University | Gecacitinib (also known as Jaktinib) JAK inhibitor | JAK1, JAK2, JAK3 | Phase 1 | Acute Graft Versus Host Disease | Dec 2027 |
Atopic Dermatitis (7) Alopecia Areata (6) Ulcerative Colitis (6) Rheumatoid Arthritis (6) Vitiligo (6) Hidradenitis Suppurativa (5) Acute Lymphoblastic Leukemia (4) Rheumatoid Arthritis (RA (3) Ulcerative Colitis Acute (3) Acute Myeloid Leukemia (3) Severe Alopecia Areata (3) Juvenile Idiopathic Arthritis (JIA) (2)
small molecule (15), mixed (1)
Pfizer (2) AbbVie (2) First Affiliated Hospital of Zhejiang University (1) Sun Pharmaceutical Industries (1) Alfasigma (1) Takeda (1) Incyte (1) LEO Pharma (1) Eisai (1) City of Hope Medical Center (1) Shixiu Wu (1) M.D. Anderson Cancer Center (1) Fudan University (1) Suzhou Zelgen Biopharmaceuticals (1)
JAK1 (15) JAK2 (15) TYK2 (12) ITK (1) BMX (1) TEC (1) TXK (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.